ATAI Live-Signale | Maximieren Sie Profite mit Getagraph.com

VERKAUFEN 108330 min ago

@ $1.778

Ausgestellt: 14 Feb 2024 @ 15:30

Rendite: 10.79%

Vorheriges Signal: Feb 12 - 20:27

Vorheriges Signal: Kaufen

Rendite: -3.36 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Stats
Tagesvolumen	1.15M
Durchschnittsvolumen	1.61M
Marktkapitalisierung	329.80M
EPS	$0 ( 2024-03-29 )
Nächstes Ertragsdatum	( $-0.200 ) 2024-05-09
Last Dividend	$6.00 ( 2018-08-27 )
Next Dividend	$0 ( N/A )
P/E	-7.88
ATR14	$0.00600 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Apeiron Investment Group Ltd.	Buy	147 950	Convertible Notes
2024-04-15	Apeiron Investment Group Ltd.	Sell	147 950	Convertible Notes
2024-04-02	Johnson Anne Nagengast	Sell	27 410	Common Shares
2024-04-02	Rao Srinivas	Sell	61 640	Common Shares
2024-04-02	Kirpekar Sahil	Sell	35 801	Common Shares

INSIDER POWER
56.52
Last 90 transactions
Buy: 18 737 833 \| Sell: 13 770 797

Volumen Korrelation

Lang: 0.05 (neutral)

Kurz: 0.95 (very strong)

Signal:(57.012) Expect same movement, but be aware

ATA Inc. Korrelation

10 Am meisten positiv korreliert
LLNW	0.94
PAVM	0.928
SVOK	0.916
IMCC	0.913
NVTSW	0.913
SWAV	0.912
QTEK	0.912
RDHL	0.911
QAT	0.91
NKTX	0.91

10 Am meisten negativ korreliert
ITMR	-0.949
AVEO	-0.939
GAINM	-0.933
XOMAO	-0.931
DVCR	-0.925
ALXN	-0.923
PPD	-0.923
GLLI	-0.923
MLCO	-0.923
ACAB	-0.922

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

ATA Inc. Korrelation - Währung/Rohstoff

-0.15
( neutral )

0.21
( neutral )

0.00
( neutral )

-0.49
( neutral )

0.31
( neutral )

-0.73
( moderate negative )

ATA Inc. Finanzdaten

Annual	2023
Umsatz:	$314 000
Bruttogewinn:	$-5 000.00 (-1.59 %)
EPS:	$-0.250

FY	2023
Umsatz:	$314 000
Bruttogewinn:	$-5 000.00 (-1.59 %)
EPS:	$-0.250

FY	2022
Umsatz:	$233 000
Bruttogewinn:	$65 000.00 (27.90 %)
EPS:	$-0.910

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.100

Financial Reports:

No articles found.

ATA Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

ATA Inc. Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.430	2011-06-28
Last Dividend	$6.00	2018-08-27
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	$7.36	--
Avg. Dividend % Per Year	0.00%	--
Score	0.25	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2025-09-15)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

0.25

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-128.70	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.138	1.200	-4.59	-5.51	[0 - 0.3]
returnOnEquityTTM	-0.920	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	9.22	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.78	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.24	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0528	-1.500	9.12	-10.00	[0 - 0.6]
interestCoverageTTM	-46.97	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.524	2.00	-0.175	-0.349	[0 - 30]
freeCashFlowPerShareTTM	-0.528	2.00	-0.264	-0.528	[0 - 20]
debtEquityRatioTTM	0.0637	-1.500	9.75	-10.00	[0 - 2.5]
grossProfitMarginTTM	-0.710	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-397.42	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-5.38	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.00107	0.800	-3.33	-2.66	[0.5 - 2]
Total Score				-2.40

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-7.59	1.000	-0.867	0	[1 - 100]
returnOnEquityTTM	-0.920	2.50	-7.29	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.528	2.00	-0.176	-0.528	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.524	2.00	-0.175	-0.349	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.0796	1.500	-3.86	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-265.15	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.74

ATA Inc.

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.